Trial Profile

A phase III trial evaluating ATI-502 in patients with Alopecia Areata

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 16 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ifidancitinib (Primary)
Indications Alopecia areata
Focus Therapeutic Use
Sponsors Aclaris Therapeutics

Most Recent Events

16 May 2019 New trial record
08 May 2019 According to an Aclaris Therapeutics media release, the company plans to initiate this trial in the first half of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com